Última actualização :
28/04/2024
Antifúngico   Amphotericin B  
Injetável
Aerossol Colutório Solução oftálmica Solução Oral
Estabilidade em soluções simples Estabilidade em misturas Factores que afectam a sua estabilidade Compatibilidade Método de administração Bibliografía Pdf
   Estrutura química  

Nomes comerciais nos diversos países   Nomes comerciais nos diversos países     

OS NOMES COMERCIAIS SÃO INDICATIVOS E OS EXCIPIENTES DA FORMULAÇÃO PODEM SER DIFERENTES CONFORME O PAÍS E FABRICANTE.

Amfotericina B Argentina, Brasil, Equator, Espanha
Amphotericin B Austria, Emirados Árabes Unidos, Estados Unidos de América
Amphotericina B Chilli, Colômbia, Peru
Amphotericine B Hungria
Fungizona Espanha
Fungizone Alemanha, Australia, Bélgica, Canadá, Colômbia, Dinamarca, Finlandia, França, Gran-bretanha, Grècia, Hungria, Índia, Irã, Irlanda, Itália, Luxemburgo, Malásia, Marrocos, Noruega, Nova Zelândia, Países Baixos, Peru, Portugal, Suècia, Suicia, Tunísia, Turquia, Venezuela
Terix México
Bibliografía   Injetável   Bibliografía : Amphotericin B  
Tipo Publicação
3 Jornal Trissel LA, Martinez JF.
Compatibility of amifostine with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
12 Jornal Owens LC, Fleming RA, Restino MS, Cruz JM, Hurd DD.
Stability of amphotericin B 0.05 and 0.5 mg/ml in 20% fat emulsion.
Am J Health-Syst Pharm 1997 ; 54: 683-686.
36 Jornal Alex S, Gupta SL, Minor JR, Turcovski-Corrales S, Gallelli JF, Taub D, Piscitelli SC.
Compatibility and activity of aldesleukin (recombinant interleukin-2) in presence of selected drugs during simulated Y-site administration: Evaluation of three methods.
Am J Health-Syst Pharm 1995 ; 52: 2423-2426.
59 Jornal Trissel LA, Gilbert DL, Martinez JF, Kim MC.
Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
73 Jornal Lor E, Takagi J.
Visual compatibility of foscarnet with other injectable drugs.
Am J Hosp Pharm 1990 ; 47: 157-159.
81 Jornal Trissel LA, Martinez JF.
Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 672-678.
84 Jornal Trissel LA, Martinez JF.
Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 495-499.
99 Jornal Trissel LA, Martinez JF.
Compatibility of aztreonam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
169 Jornal Trissel LA, Martinez JF.
Physical compatibility of melphalan with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1993 ; 50: 2359-2363.
182 Jornal Trissel LA, Gilbert DL, Martinez JF.
Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 56-60.
198 Jornal Gayed AA, Kheshary PR, Hinkle RL.
Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection.
Am J Health-Syst Pharm 1995 ; 52: 516-520.
201 Jornal Thompson DF, Allen LV, Stiles ML.
Visual compatibility of enalaprilate with selected intravenous medications during simulated Y-site injection.
Am J Hosp Pharm 1990 ; 47: 2530-2531.
215 Jornal Keyi X, Gagnon N, Bisson C, Desmarais M, LeBel M.
Stability of famotidine in polyvinyl chloride minibags and polypropylene syringes and compatibility of famotidine with selected drugs.
Ann Pharmacotherapy 1993 ; 27: 422-426.
244 Jornal Trissel LA, Martinez JF.
Compatibility of filgrastim with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1907-1913.
248 Jornal Trissel LA, Martinez JF.
Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection.
Am J Hosp Pharm 1993 ; 50: 300-304.
249 Jornal Trissel LA, Martinez JF.
Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251 Jornal Trissel LA, Gilbert DL, Martinez JF.
Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
253 Jornal Trissel LA, Chandler SW, Folstad JT.
Visual compatibility of amsacrine with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1990 ; 47: 2525-2528.
256 Jornal Inagaki K, Takagi J, Lor E, Lee KJ, Nii L, Gill MA.
Stability of fluconazole in commonly used intravenous antibiotic solutions.
Am J Hosp Pharm 1993 ; 50: 1206-1208.
265 Jornal Trissel LA.
Amphotericin B does not mix with fat emulsion.
Am J Health-Syst Pharm 1995 ; 52: 1463-1464.
266 Jornal Patel PR.
Compatibility of meropenem with commonly used injectable drugs.
Am J Health-Syst Pharm 1996 ; 53: 2853-2855.
270 Jornal Heide PE.
Precipitation of amphotericin B from IV fat emulsion.
Am J Health-Syst Pharm 1997 ; 54: 1449.
280 Jornal Allen LV, Stiles ML, Prince SJ, Sylvestri MF.
Stability of cefpirome sulfate in the presence of commonly used intensive care drugs during simulated Y-site injection.
Am J Health-Syst Pharm 1995 ; 52: 2427-2433.
283 Jornal Lee MD, Hess MM, Boucher BA, Apple AM.
Stability of amphotericin B in 5% dextrose injection stored at 4 or 25°C for 120 hours.
Am J Hosp Pharm 1994 ; 51: 394-396.
285 Jornal Elmore RL, Contois ME, Kelly J, Noe A, Poirier A.
Stability and compatibility of admixtures of intravenous ciprofloxacin and selected drugs.
Clin Ther 1996 ; 18: 246-255.
299 Jornal Trissel LA, Martinez JF, Gilbert DL.
Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300 Jornal Trissel LA, Gilbert DL, Martinez JF.
Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301 Jornal Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM.
Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307 Jornal Trissel LA, Martinez JF.
Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1792-1799.
334 Jornal Trissel LA, Tramonte SM, Grilley BJ.
Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 988-992.
335 Jornal Trissel LA, Bready BB, Kwan JW, Santiago NM.
Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 402-406.
337 Jornal Bashaw ED, Amantea MA, Minor JR, Galleli JF.
Visual compatibility of zidovudine with other drugs during simulated Y-site administration.
Am J Hosp Pharm 1988 ; 45: 2532-2533.
435 Jornal Wiest DB, Maish WA, Garner SS, El-Chaar GM.
Stability of amphotericin B in four concentrations of dextrose injection.
Am J Hosp Pharm 1991 ; 48: 2430-2433.
436 Jornal Mitrano FP, Outman WR, Baptista RJ, Palombo JD.
Chemical and visual stability of amphotericin B in 5% dextrose injection stored at 4°C for 35 days.
Am J Hosp Pharm 1991 ; 48: 2635-2637.
439 Jornal Kintzel PE, Kennedy PE.
Stability of amphotericin B in 5% dextrose injection at concentrations used for administration through a central venous line.
Am J Hosp Pharm 1991 ; 48: 283-285.
479 Jornal Min DI, Brown T, HWang GC.
Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 2964-2966.
492 Jornal Trissel LA, Parks NPT, Santiago NM.
Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 2186-2189.
496 Jornal Lor E, Sheybani T, Takagi J.
Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration.
Am J Hosp Pharm 1991 ; 48: 744-746.
497 Jornal Kintzel PE, Kennedy PE.
Stability of amphotericin B in 5% dextrose injection at 25°C.
Am J Hosp Pharm 1991 ; 48: 1681.
604 Laboratório Stabilité des médicaments dans l'Intermate® SV50, 100, 200
Baxter 1998
682 Jornal Raymond GG, Davis RL.
Physical compatibility and chemical stability of amphotericin B in combination with magnesium sulfate in 5% dextrose injection.
Ann Pharmacotherapy 1991 ; 25: 123-126.
793 Jornal Ranch?re JY, Latour JF, Fuhrmann C, Lagallarde C, Loreuil F.
Amphotericin B intralipid formulation: stability and particule size.
J Antimicrob Chemother 1996 ; 37: 1165-1169.
892 Jornal Kintzel PE, Smith GH.
Practical guidelines for preparing and administering amphotericin B.
Am J Hosp Pharm 1992 ; 49: 1156-1164.
905 Jornal Trissel LA, Martinez JF.
Screening teniposide for Y-site physical incompatibilities.
Hosp Pharm 1994 ; 29: 1010-1017.
984 Jornal Ericsson O, Hallmen AC, Wikstrom I.
Amphotericin B is incompatible with lipid emulsions.
Ann Pharmacotherapy 1996 ; 30: 298.
1057 Jornal Cutie MR.
Compatibility of verapamil hydrochloride injection with commonly used additives.
Am J Hosp Pharm 1983 ; 40: 1205-1207.
1135 Jornal Baltz JK, Kennedy P, Minor JR, Gallelli J.
Visual compatibility of foscarnet with other injectable drugs during simulated Y-site administration.
Am J Hosp Pharm 1990 ; 47: 2075-2077.
1172 Jornal Jurgens RW, DeLuca PP, Papadimitriou D.
Compatibility of amphotericin B with certain large-volume parenterals.
Am J Hosp Pharm 1981 ; 38: 377-378.
1201 Jornal Yuhas EM, Lofton FT, Rosenberg HA, Mayron D, Baldinus JG.
Cimetidine hydrochloride compatibility III: Room temperature stability in drug admixtures.
Am J Hosp Pharm 1981 ; 38: 1919-1922.
1410 Jornal Trissel LA, Martinez JF, Simmons M.
Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 141-145.
1415 Jornal Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M.
Compatibility of medications with 3-in-1 parenteral nutrition admixtures.
JPEN 1999 ; 23: 67-74.
1423 Jornal Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518.
1498 Jornal Cleary JD.
Amphotericin B formulated in a lipid emulsion.
Ann Pharmacotherapy 1996 ; 30: 409-412.
1611 Jornal Chalmers JR, Bobek MB, Militello MA.
Visual compatibility of amiodarone hydrochloride injection with various intravenous drugs.
Am J Health-Syst Pharm 2001 ; 58: 504-506.
1625 Jornal Trissel LA, Saenz C, Williams YW, Ingram D.
Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2001 ; 5: 314-321.
1703 Jornal Schuster F, Bernard R.
Kompatibilität von enalaprilat i.v. mit ausgewählten arzneimitteln.
Krankenhauspharmazie 1995 ; 16: 101-103.
1712 Jornal Trissel LA, Saenz CA.
Compatibility screening of Precedex during simulated Y-site administration with other drugs.
Int J Pharm Compound 2002 ; 6: 230-233.
1713 Jornal Trissel LA, Saenz CA.
Compatibility screening of bivalirudin during simulated Y-site administration with other drugs.
Int J Pharm Compound 2002 ; 6: 311-315.
1721 Jornal Trissel LA, Williams KY, Baker MB.
Compatibility screening of Hextend during simulated Y-site administration with other drugs.
Int J Pharm Compound 2001 ; 5: 69-72.
1754 Jornal Trissel LA, Gilbert DL, Wolkin AC.
Compatibility of docetaxel with selected drugs during simulated Y-site administration.
Int J Pharm Compound 1999 ; 3: 241-244.
1803 Jornal Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB.
Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2003 ; 60: 80-85.
1907 Jornal Burger DE, Caldwell JW.
Sustaining treatment of coccidioidal meningitidis by extending the stability of amphotericin B.
Hosp Pharm 2004 ; 39: 554-557.
1925 Jornal Trissel LA , Williams KY, Gilbert DL.
Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions.
J Am Pharm Assoc 2000 ; 40: 515-519.
1953 Jornal Trissel LA, Saenz CA, Ogundele AB, Ingram DS.
Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1982 Jornal Trissel LA, Ogundele AB.
Compatibility of anidulafungin with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2005 ; 62: 834-837.
2043 Jornal Walker S, Tailor SAA, Lee M, Louie L, Louie M, Simor AE.
Amphotericin B in lipid emulsion : stability, compatibility, and in vitro antifungal activity.
Antimicrob Agents Chemother 1998 ; 42: 762-766.
2090 Jornal Pere H, Chasse V, Forest JM, Hildgen P.
Compatibility of injectable pantoprazole in Y-site administration.
Pharmactuel 2004 ; 37: 193-196.
2247 Jornal Chan P, Heatherly K, Kupiec T.C, Trissel L.A.
Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2008 ; 12, 3: 276-278.
2262 Jornal Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D.
Compatibility of doripenem with other drugs during simulated Y-site administratioN
Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2269 Jornal Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H.
Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
3152 Jornal Kumar A, Mann HJ.
Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2010 ; 67: 1640-1644.
3216 Jornal Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G.
Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y.
Pharmactuel 2011 ; 44, 1 : 14-18
3249 Jornal Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB.
Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3254 Jornal Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L.
Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration
Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3332 Laboratório Tigecycline (Tigacyl®) - Summary of Product characteristics
Pfizer 2012
3408 Jornal Tollec S, Touzin K, Pelletier E, Forest J.M.
Evaluation visuelle de la compatibilité physique de la naloxone avec d’autres médicaments intraveineux usuels.
Pharmactuel 2013 ; 46, 1 : 16-21.
3539 Laboratório Bivalirudin (Angiox®) - Summary of Product Characteristics.
The Medecines Company 2013
3549 Laboratório Amikacine B Braun - Résumé des caractéristiques du produit.
B Braun 2012
3560 Laboratório Linezolid (Zyvox®) - Summary of Product Characteristics
Pharmacia 2013
3564 Laboratório Rocuronium B Braun - Résumé des caractéristiques du produit.
B Braun 2012
3585 Laboratório Benzylpenicillin sodium - Summary of Product Characteristics
Genus Pharmaceuticals 2008
3591 Laboratório Amphotericine B (Fungizone®) - Résumé des caractéristiques du produit
Bristol Myers Squibb 2011
3638 Laboratório Dopamin (Dopamine 40 mg/mL sterile concentrate®) - Summary of Product Characteristics
Hospira 2010
3644 Laboratório Calcium gluconate® - Summary of Product Characteristics
Hameln Pharmaceuticals 2010
3662 Laboratório Foscavir (Foscarnet®) - Summary of Product Characteristics
Clinigen 2014
3766 Jornal Forrest J.M, Hildgen P.
Compatibilité de l’acétylcystéine injectable lors de son administration en Y avec d’autres médicaments usuels
Pharmactuel 2014 ; 47, 3 : 161-165.
3767 Jornal Legris M.E, Lavoie A, Forrest J.M, Hildgen P.
Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels.
Pharmactuel 2014 ; 47, 3 : 167-172.
3791 Poster Sadou Yaye H, Burtet E, Hamel C, Aljhni R, Gard C, Tilleul P.
Étude de la compatibilité physico-chimique du phloroglucinol injectable durant les mélanges au sein des tubulures en Y.
Apifh Congress, Paris November 2014 2014
3828 Poster Thabit A.K, Hamada Y, Nicolau D.P.
Ceftozolane/tazobactam physical compatibility during simulated Y-site administration.
ASHP Midyear 2015
3829 Poster So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L.
Compatibility of isavunazonium sulfate during simulated Y-site administration.
ASHP Midyear 2015
3869 Jornal Sun P, Chen J, Zhang Z, Gao X, Chen P, Li X.
Influence of 5% dextrose volume on amphotericin B deoxycholate preparation
J Pharm Pharmacol 2016 ; 68: 433-438.
3871 Poster Soussi M.A, Soualah-alila R, jenene F, Lazreg O, Razgallah Khrouf M.
Peut-on administrer le céfotaxime en Y avec d'autres médicaments injectables ?
Synprefh Congress Clermont Ferrand, France 2016
3883 Laboratório Ceftazidime - Résumé des caractéristiques du produit
Arrow 2016
3968 Laboratório Ringer lactate - Résumé des Caractéristiques du Produit
Fresenius Kabi 2015
4055 Jornal Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D.
Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145 Jornal Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P.
Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4528 Jornal Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N.
Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration.
Int J Pharm Compound 2021 ;25,1:52-61
4543 Jornal Senarathna G, Strunk T, Petrovski M, Batty K.
Physical compatibility of pentoxifylline and intravenous medications.
Archives of Disease in Childhood 2018 ;104:292–295.
4650 Laboratório Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021.
Advanz Pharma 2021

  Mentions Légales